A theory posits that an overabundance of a specific neurotransmitter, or heightened sensitivity to it, in particular brain regions is associated with the manifestation of psychotic symptoms, most notably those observed in schizophrenia. This explanation suggests that irregularities in neurotransmitter activity contribute significantly to the cognitive and perceptual disturbances characteristic of the disorder. For instance, excessive signaling of this neurotransmitter in the mesolimbic pathway is thought to underlie positive symptoms such as hallucinations and delusions.
This theoretical framework is significant because it has substantially influenced the development of antipsychotic medications. Many of these drugs function by blocking the receptors for this neurotransmitter, thereby reducing its activity in the brain and alleviating psychotic symptoms. Historically, the observation that drugs which increased the activity of this neurotransmitter could induce psychotic-like symptoms further supported this understanding of schizophrenia’s neurochemical basis. However, it is crucial to note that the relationship is complex, and other neurotransmitters and brain structures are also implicated in the disorder.